Nature Reviews Clinical Oncology, Published online: 06 November 2026; doi:10.1038/s41571-026-01227-x Unprecedented OS with the addition of tarlatamab to first-line maintenance therapy for ES-SCLC
David Killock. Unprecedented OS with the addition of tarlatamab to first-line maintenance therapy for ES-SCLC. // Nature Reviews Clinical Oncology. – 2026. – DOI: 10.1038/s41571-026-01227-x. – URL: https://www.nature.com/articles/s41571-026-01227-x
David Killock (2026). Unprecedented OS with the addition of tarlatamab to first-line maintenance therapy for ES-SCLC. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-026-01227-x
David Killock. “Unprecedented OS with the addition of tarlatamab to first-line maintenance therapy for ES-SCLC.” Nature Reviews Clinical Oncology, 2026. doi:10.1038/s41571-026-01227-x.
@article{Killock2026,
title = {Unprecedented OS with the addition of tarlatamab to first-line maintenance therapy for ES-SCLC},
author = {Killock, David},
journal = {Nature Reviews Clinical Oncology},
year = {2026},
doi = {10.1038/s41571-026-01227-x},
url = {https://www.nature.com/articles/s41571-026-01227-x}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment